» Articles » PMID: 580343

Mammary Tumour Inhibition and Subacute Toxicity in Rats of Prednimustine and of Its Molecular Components Chlorambucil and Prednisolone

Overview
Specialties Pharmacology
Toxicology
Date 1978 Mar 1
PMID 580343
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Prednimustine, a chlorambucil ester of pregnisolone, retarded growth of DMBA-induced mammary tumours in rats and reduced the number of tumours. A combination of chlorambucil and prednisolone (C + P) in the same proportion as in prednimustine, had similar effects, 8 and 26 mg per kg of the C + P combination being equipotnet to 16 and 64 mg per kg of prednimustine, respectively. The mortality figures suggested that prednimustine was considerably less toxic than equipotent doses of C + P. This toxicity difference was confirmed in a parallel investigation of the subacute toxicity in rats of prednimustine and C + P. This study showed that the mortality, reduction of lymphocytes and platelets, and bone marrow depression was much lower after pregnimustine than after equimolar amounts of the C + P combination. The results suggest that the low toxicity of prednimustine makes this drug a better cytostatic agent than the C + P combination treatment.

Citing Articles

Cauchy combination omnibus test for normality.

Meng Z, Jiang Z PLoS One. 2023; 18(8):e0289498.

PMID: 37535617 PMC: 10399863. DOI: 10.1371/journal.pone.0289498.


The pharmacokinetics of prednimustine and chlorambucil in the rat.

Newell D, Shepherd C, HARRAP K Cancer Chemother Pharmacol. 1981; 6(1):85-91.

PMID: 7273268 DOI: 10.1007/BF00253015.


Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: a phase I-II study.

Mouridsen H, Boesen E Breast Cancer Res Treat. 1983; 3(1):85-9.

PMID: 6871484 DOI: 10.1007/BF01806238.


Cytotoxicity and metabolism of prednimustine, chlorambucil and prednisolone in a Chinese hamster cell line.

Gunnarsson P, Liljekvist J Cancer Chemother Pharmacol. 1986; 16(2):85-90.

PMID: 3948307 DOI: 10.1007/BF00256154.


Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).

Christensson P, Gunnarsson K, Gunnarsson P, Jensen G, Polacek J, Stamvik A Invest New Drugs. 1988; 6(1):19-30.

PMID: 3410663 DOI: 10.1007/BF00170775.